Gufic Biosciences Limited

As of June 30, 2026, Gufic Biosciences Limited carries a market capitalization of 40.82B, placing it among publicly traded companies globally. Its enterprise value stands at 40.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gufic Biosciences Limited has 100.28M shares outstanding.

As of June 30, 2026, Gufic Biosciences Limited trades at a trailing price-to-earnings ratio of 55.59.

As of June 30, 2026, Gufic Biosciences Limited trades at an EV/EBITDA multiple of 24.79 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 30.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 40.82B versus a market cap of 40.82B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.01M in revenue per employee across its workforce of 2,445.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gufic Biosciences Limited recorded 258.59M in income tax expense. That works out to an effective tax rate of 26.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 993.14M, leaving 734.57M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Gufic Biosciences Limited's stock has gained approximately 13.78% over the past 52 weeks. The 50-day moving average sits at 421.28, while the 200-day moving average is 350.72.

Over the twelve months ended June 30, 2026, Gufic Biosciences Limited generated 9.81B in revenue and converted that into 734.57M in net income, yielding earnings per share of 7.32. EBITDA reached 1.65B, while operating income came in at 1.34B.

Over the twelve months ended June 30, 2026, Gufic Biosciences Limited posted a gross margin of 55.62, reflecting its pricing power and cost economics. The operating margin of 13.64 and net profit margin of 7.49 provide insight into operational efficiency.

Gufic Biosciences Limited's most recent stock split took place on October 29, 2002 with a 1:10 split ratio.